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Introduction
Primary central nervous system lymphoma (PCNSL) is a
separate group of non-Hodgkin lymphoma confined to the
central nervous system (CNS). Incidence has increased during
the last decades, particularly in elderly patients.1,2 Median age
at diagnosis has increased from 60.5 to 65 years during the
last 20 years.3 In 2002, the Nordic Lymphoma Group pub-
lished a phase ll trial investigating whether an age-adjusted
regimen consisting of chemotherapy alone could induce
durable remissions in PCNSL patients.4 The responses
achieved were of short duration. Due to profound toxicity,
the study was closed after the enrolment of only 30 patients.
Although treatment results in PCNSL patients have improved
during recent years, the prognosis still remains poor in the
majority of patients, especially in the elderly. The first
prospective phase ll trial designed with special attention to
elderly patients reported a median overall survival (OS) of
14.3 months obtained by a chemotherapy-alone regimen
(high-dose methotrexate (HD-MTX), lomustine, procar-
bazine and dexamethasone).5 HD-MTX-based chemotherapy
combined with whole brain radiotherapy produced a median
survival time of 50 months in patients aged under 60 years
and 21.8 months in patients aged over 60 years.6 Promising
results were obtained in younger patients by an HD-MTX
and HD-AraC-based multi-agent regimen including intraven-
tricular treatment and omitting radiotherapy (hereafter
referred to as the Bonn protocol) yielding an OS at five years
of 75% in patients younger than 61 years as compared to only
19% in patients older than 60 years.7
The aim of the present study was to investigate the efficacy
and safety of a systemic HD-MTX/HD-AraC-based multi-
agent immunochemotherapy regimen with cerebrospinal
fluid (CSF) targeted treatment but without radiotherapy in
newly diagnosed PCNSL patients. The goal of our study was
to find a treatment concept with improved outcome and/or
less toxicity than those reported hitherto for this patient
group. In the extension of the Bonn study,7 we added the fol-
lowing modifications. 1) Rituximab was added to the induc-
tion as the majority of PCNSL are CD20+ diffuse large B-cell
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The Nordic Lymphoma Group has conducted a phase ll trial in newly diagnosed primary central nervous system
lymphoma patients applying an age-adjusted multi-agent immunochemotherapy regimen, which in elderly
patients included temozolomide maintenance treatment. Patients aged 18-75 years were eligible. Thirty-nine
patients aged 18-65 years and 27 patients aged 66-75 years were enrolled. The median age of the two age groups
was 55 and 70 years, respectively. The overall response rate was 73.8% for the entire cohort: 69.9% in the younger
and 80.8% in the elderly subgroup. With a median follow up of 22 months, the 2-year overall survival probability
was 60.7% in patients aged 65 years or under and 55.6% in patients aged over 65 years (P=0.40). The estimated
progression-free survival at two years was 33.1% (95%CI: 19.1%-47.9%) in patients aged under 65 years and
44.4% (95%CI: 25.6%-61.8%) in the elderly subgroup (P=0.74). Median duration of response was ten months in
the younger subgroup, and not reached in the elderly patient subgroup (P=0.33). Four patients aged 64-75 years
(6%) died from treatment-related complications. Survival in the two age groups was similar despite a de-escalation
of induction treatment in patients aged over 65 years. Duration of response in elderly patients receiving mainte-
nance temozolomide was longer than in the younger age subgroup. While toxicity during induction is still of con-
cern, especially in the elderly patients, we conclude from these data that de-escalation of induction therapy in eld-
erly primary central nervous system lymphoma patients followed by maintenance treatment seems to be a prom-
ising treatment strategy. (clinicaltrials.gov identifier:01458730)
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ABSTRACT
lymphomas (DLBCL) and it was previously shown that
the addition of rituximab to CHOP chemotherapy has
improved the prognosis in DLBCL outside the brain.8 2)
The intraventricular MTX/cytarabine treatment of the
Bonn protocol requiring an Ommaya reservoir was
replaced by intraspinal administration of liposomal cytara-
bine in view of the expected lower risk of procedure-relat-
ed infections. 3) The infusion time of MTX was reduced
from 24 h to 3 h as a higher drug penetration has been
achieved by a shorter infusion time.9 4) Importantly, given
the cited literature, the treatment was age-adjusted with
patients aged over 65 years having cyclophosphamide of
the second and fifth and ifosfamide of the fourth
chemotherapy cycle replaced by the less toxic agent temo-
zolomide (TZM). Vincristine was also not part of the
study treatment for the elderly patients. 5) To improve dis-
ease control in responding patients aged over 65 years in
whom induction intensity was reduced, maintenance
treatment with TZM was added. This was done because
TZM, an oral alkylating agent, can penetrate the intact
blood brain barrier,10 and because it has shown activity
and a favorable toxicity profile in PCNSL patients.11 
Methods
Study design
This was a prospective multicenter phase ll trial.
Eligibility  
Eligibility criteria were: immunocompetent patients aged 18-75
years with newly diagnosed histologically-confirmed PCNSL.
Patients pre-treated with steroids were eligible. There were no
limitations for inclusion with regard to Eastern Co-operative
Oncology Group (ECOG) performance score. Exclusion criteria
were: lymphoma outside the CNS, HIV positivity, inadequate
bone marrow function, liver disease, creatinine clearance less than
60 mL/min, organ transplantation, prior radiotherapy to the brain,
previous malignancy unless disease free for at least five years,
pregnancy or lactation.  The study was approved by the local eth-
ical committees and conducted in agreement with the Declaration
of Helsinki and Good Clinical Practice Guidelines. Written
informed consent from all patients or guardians was required. 
Base-line evaluation
Pre-treatment evaluation, performed according to international
guidelines,12 included magnetic resonance imaging (MRI) of the
brain performed before and after stereotactic biopsy/operation.
Ocular involvement was ruled out by slit lamp examination and
systemic involvement by total body computed tomography, bone
marrow aspirate and biopsy. Ultrasonic scan of testes was per-
formed in male patients aged over 60 years. Cerebrospinal fluid
(CSF) was analyzed for protein, cell count, cytology and
immunophenotype.
Study treatment
Patients aged 18-65 years and patients aged 66-75 years received
immunochemotherapy as shown in Online Supplementary Tables
S1 and S2, respectively. Drug infusion time was 3 h for HD-MTX
and HD-AraC. Maintenance treatment with TZM 150 mg/m2 days
1-5 at an interval of 28 days was administered to elderly patients
who responded to induction therapy. Maintenance treatment was
started one month after completion of induction and continued for
one year or until relapse/progression. Additional treatment in case
of ocular lymphoma was not part of our protocol. 
Response assessment
Response was assessed after cycles 2, 4 and 6 and evaluated
according to international response criteria.12 Patients not respond-
ing to therapy and patients with later disease progression were
taken off study. In case of stable disease (SD) at the first response
assessment (after two HD-MTX cycles) the study treatment was
continued as planned. Patients not achieving complete response
(CR) at completion of planned therapy went off study and were
followed for survival only.  During follow up, MRI of the brain
was performed every three months the first year, twice a year for
four years, and once a year thereafter. Toxicity was graded accord-
ing to Common Toxicity Criteria (CTC, version 2.0).
Neurotoxicity was evaluated by means of Mini Mental State
Examination (MMSE) and Functional Independent Measure (FIM)
at baseline and at each response assessment.
Statistical analysis
All patients enrolled (n=66) were included in the final analyses.
The primary end point was OS and the secondary end points
were: response rate (RR), progression-free survival (PFS), systemic
toxicity, and neurotoxicity. OS was calculated from the date of
diagnosis to death or latest follow up. PFS was calculated from the
date of diagnosis to the date of progression, death of any cause or
latest date of follow up.  Duration of response (DOR) was calcu-
lated from the date of first documentation of CR to the date of
progression, death or latest follow up. 
Results
Patients’ characteristics
Sixty-six patients (35 male and 31 female patients) from
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Table 1. Patients’ characteristics.
Whole group Patient age Patient age 
< 66 years 66-75 years
n=66 n=39 n=27
Median age 64 55 70 
(range) (40-75) (40-65) (66-75)
Male 35 23 12
Female 31 16 15
ECOG performance
Median 1 1 1
ECOG 0 N=19 N=11 N=8
ECOG 1 N=17 N=11 N=6
ECOG 2 N=14 N=8 N=6
ECOG 3 N=12 N=8 N=4
ECOG 4 N=4 N=1 N=3
Deep brain structures involved 43 24 19
Ocular lymphoma 4 1 3
N. of tumors
Single tumor 24 14 10
Multiple tumors 42 25 17
Histology
Diffuse large B-cell lymphoma 65
Peripheral T-cell lymphoma 1
Stereotactic biopsy 34 19 15
Surgical biopsy 32 20 12
Spinal fluid analysis performed 49 26 23
Spinal fluid analysis 17 13 4
not performed
twelve centers in Sweden, Norway, Denmark and Finland
were enrolled from May 2007 to October 2010. Patients’
characteristics are summarized in Table 1. Median age was
64 years for the entire patient cohort (range 40-75 years),
55 years in 39 younger patients (range 40-65 years), and 70
years in 27 elderly patients (range 66-75 years). Median
ECOG performance status was 1 (range 0-4). Histology
was DLBCL in all patients but one who had a peripheral
T-cell lymphoma. Ocular lymphoma was found in 4 cases.
None of the male patients aged 60 years or older was diag-
nosed with testicular lymphoma. According to the
Memorial Sloan-Kettering Cancer Center (MSKCC) prog-
nostic model,13 9 patients were class 1 (13.6%), 31 patients
class 2 (47.0%), and 26 patients class 3 (39.4%).
Cerebrospinal fluid findings
Cerebrospinal fluid (CSF) analysis was performed at
diagnosis in 49 patients and not performed in 17 patients.
The cell number was normal in 22 cases, increased in 18,
and not evaluated in 9 cases.  Cytology was positive for
lymphoma involvement in 8 patients, negative in 36, and
not examined in 5 patients. Flow cytometry was positive
in only 2 of 30 cases examined. CSF protein was elevated
in 24 cases, normal in 15 cases, and not examined in 10
cases. 
Treatment
All patients started treatment with a median time of 10
days (0-42 days) from diagnosis to first day of therapy.
Forty-two patients (63.6%) received the planned six cours-
es of induction chemotherapy. A reduced number of
chemotherapy cycles (n=1-5) were delivered to the
remaining 24 patients due to poor performance status in 6,
toxicity in 9 and early progression in 8 patients. The rea-
sons for discontinuation of chemotherapy are summa-
rized in the Online Supplementary Table S3. One patient
with a partial response (PR) went off study after four
chemotherapy cycles due to lack of additional response to
the third and fourth cycle. Treatment delay was defined as
a chemotherapy delivery more than a week behind sched-
ule. Treatment was delayed for 8-53 days (median 14
days) in 15 of 62 patients. Intraspinal treatment was lipo-
somal cytarabine 50 mg administered by lumbar puncture
at day 2 during the four HD-MTX courses. A total of 200
liposomal cytarabine treatments, (median 4, range 1-4)
were delivered to 66 patients. Maintenance treatment
with temozolomide was started in 15 of 27 elderly
patients and not started in 12 patients due to toxicity dur-
ing the induction therapy in 6, early progression in 3 and
poor performance in 3 patients. Median number of TZM
treatments delivered was 11 (range 1-12).
Response to induction treatment
In one of 66 patients, response to induction chemother-
apy could not be assessed as the treatment was terminated
after the first cycle due to poor clinical condition. In addi-
tion, 3 patients completed only one chemotherapy cycle
due to progressive disease (PD) after the first cycle. These
3 patients were included in the response analysis. Best
response documented during therapy was CR in 42
(64.6%) and PR in 17 patients (26.2%); overall response
rate (ORR) 90.8%. Six patients (9.2%) did not respond to
induction chemotherapy (SD 2, PD 4). However, in 11
patients who initially responded to therapy (achieved
either CR or PR after 2 or 4 chemotherapy courses), the
final response assessment at completion of therapy
showed PD. When these cases are included in the analysis
as PD, the overall response rate for the entire cohort was
73.8%; 69.2% in the younger and 80.8% in the elderly
subgroup (Table 2).  At a median follow up of 22 months,
relapse after achieving CR occurred in 17 of 27 patients
(63%) under the age of 66 years and in 5 of 18 elderly
patients (28%). All 4 patients with ocular lymphoma went
off study after 1-4 cycles of chemotherapy because of pro-
gression or poor clinical condition. 
Response to maintenance treatment
Disease status at start of maintenance was PR in 3
patients and CR in 12 patients.  During maintenance treat-
ment, 4 CR patients progressed, 2 PR patients achieved
CR. One PR patient achieved CR at month 9 of follow up.
Survival 
Median follow up was 22 months (range 1-57 months).
The estimated 2-year OS rate for the entire patient cohort
was 58.7% (95%CI: 45.8%-69.5%) (Figure 1A). The esti-
mated 2-year OS in patients under the age of 66 years was
60.7% (95%CI: 43.3%-74.2%) and 55.6% in patients
older than 65 years (95%CI: 35.2%-71.8%; P=0.40).  The
median OS has not yet been reached in either age group
(Figure 1B). The estimated PFS at two years was 37.8%
(95%CI: 26.3%-49.3%) for the whole group (Figure 1C),
33.1% (95%CI:  19.1%-47.9%) in patients under the age
of 66 years and 44.4% (95%CI:  25.6%-61.8%; P=0.74) in
the elderly subgroup (Figure 1D). Relapse-free survival
after CR at two years was 44.1% (95%CI: 29.3%-57.9%)
(Figure 2A) with no significant difference between the two
age groups (P=0.33) (Figure 2B).  Median DOR for those
patients who achieved CR was 15 months: 10 months in
the younger patients and not reached in the elderly age
group ( P=0.33). Outcome in terms of OS was significantly
better in patients in MSKCC class 1 or 2 as compared to
MSKCC class 3 (data not shown) ( P=0.004).
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Table 2. 
Best response documented during therapy Response at completion of therapy
Age 18-65 years Age 66-75 years Age 18-65 years Age 66-75 years
n=39 n=26 n=39 n=26 
CR 27 (69.2%) 18 (69.2%) 23 (59.0%) 15 (57.7%)
PR 9 (23.1%) 5 (19.2%) 4 (10.3%) 6 (23.1%)
SD 1 (2.6%) 1 (3.8%) 0 1 (3.8%)
PD 2 (5.1%) 2 (7.7%) 12 (30.8%) 4 (15.4%)
ORR 92.3% 88.5% 69.2% 80.8%
CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; ORR: overall response rate.
Toxicity
Myelosuppression was the most common side effect
and occurred mainly after the HD-AraC cycles.
Subsequent to HD-AraC grade 3-4 anemia, neutropenia or
thrombocytopenia was reported in 16.1%, 89.3% and
80.9% of the cases, respectively. HD-MTX was relatively
well tolerated with anemia, or grade 3-4 neutropenia or
thrombocytopenia (Common Toxicity Criteria, v.2.0)
reported in 1.5%, 25.8% and 10.6% of the cases, respec-
tively. Impaired kidney function (grade 2-3) occurred in 4
patients (6.1%), and deep venous thrombosis in 7 patients
(10.6%; grade 3-4 in 4). Four patients (6%) aged 64, 66, 73
and 74 years died as a result of treatment. All treatment-
related deaths occurred after the first HD-AraC course due
to neutropenia and sepsis-induced multi-organ failure.
With respect to neurotoxicity during treatment, 16 grade
2-4 events were reported in 15 patients during induction
therapy (n=13) or maintenance therapy (n=2). The clinical
condition, onset and duration of symptoms and medica-
tion before the onset of symptoms are summarized in
Online Supplementary Table S4. Twelve patients recovered.
In 9 patients, the planned treatment was continued, but
further liposomal cytarabine was omitted in 5 patients.
Three patients did not recover and went off study.
Discussion
In this study, we have shown that the survival in elderly
patients was not compromised, and possibly even may
have been improved, by de-escalating induction and
adding maintenance therapy. The number of elderly
patients was too low, however, to allow any definite con-
clusions to be drawn. We found equally favorable
response rates in elderly and younger patients in spite of
the fact that patients with poor performance status
(ECOG 3-4) were included in our study.  It is widely
accepted that the regimens in PCNSL should contain HD-
MTX as the most important agent of induction. Even
though radiotherapy increases the remission rate, several
studies have investigated the efficacy of HD-MTX alone
or in combination with other drugs in order to avoid
radiotherapy due to the risk of long-term neurotoxicity.14
These studies have shown improvement in response rates
as compared to HD-MTX alone regimens.6,14-16 The present
study provides additional evidence of this benefit. 
An important strategy of this study was the stratifica-
tion of therapy according to age, which has been identi-
fied as the most important prognostic risk factor in PCNSL
together with performance status.13,17 The main finding of
our data, and in contrast to other studies,7,14 is that patients
in the elderly age group responded equally well as
younger patients in terms of ORR, OS and PFS, indicating
benefit of temozolomide. These findings suggest an
improvement in the elderly when compared with a report
by Pels et al. who reported age-related treatment outcome
after chemotherapy only with an estimated OS at five
years of 19% in 31 patients older than 60 years in contrast
to 75% in 30 younger patients.7
Comparison of survival outcomes between different
studies is generally difficult due to different study design,
different treatment modalities, and great variability in
patients’ characteristics. The entire cohorts treated in the
Bonn study7 and in the present study were similar in terms
of median age (62 vs. 64 years) and performance status
(Karnofsky 70 vs. ECOG 1). Also, the study treatment
with regard to younger patients was similar with the
exception of the differences in the intrathecal treatment:
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Figure 1. (A) Overall survival for the entire patient cohort. (B) Overall
survival according to age.  (C) Progression-free survival for the entire
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administration route (intraventricular vs. intraspinal),
number of treatments (6 vs. 4), and composition of treat-
ment (MTX, AraC, methylprednisolone vs. liposomal
cytarabine). Although the ORR was similar in both stud-
ies, and median OS was not reached in either, they provid-
ed different results regarding median response duration,
which was only ten months in patients aged under 66
years in the present study, and not reached in the Bonn
study after a median follow up of 26 months. This differ-
ence might be due in part to the different upper age limit
of the younger subgroup in these two studies: 65 years in
the present study versus 60 years in the Bonn study.
Notably, more than one-third of the younger patients in
the present study were 61-65 years old and duration of
response was especially short in these patients, as 8 of 14
responding patients relapsed early (median 6.3 months).
An up-dated analysis of the Bonn study has shown that
the median OS was 34 months in the elderly subgroup,
but still not reached in younger patients after a follow up
of a median 100 months.18 Age was, however, not found
to be a risk factor in a recently published Cancer and
Leukemia Group B (CALGB) study in which 44 patients
with median age of 61 years (12-76 years) were treated
with HD-MTX, rituximab and TZM induction followed
by etoposide and HD-AraC consolidation without CSF-
targeted chemotherapy.19 The median PFS in the CALGB
cohort was similar in older and younger patients.
Estimated 2-year OS of 70% for the entire CALGB cohort
was superior to the results of the present trial in which the
estimated 2-year OS survival was 58.7%. However, only
patients with ECOG performance of of 2 or less than 2
were included in the CALGB study, which could well
account for the superior survival, since we also included
patients with an ECOG performance status of 3-4.
The treatment–related mortality (TRM) of our study of
6% is comparable with other studies using HD-MTX and
HD-AraC-based chemotherapy. Pels et al.7 reported a
TRM of 9% in patients treated with basically the same
systemic chemotherapy as that used in our study. Of 41
patients enrolled in a phase II study applying the HD-
MTX and HD-AraC combination published by Ferreri et
al.,21 4 patients (9.7%) died due to treatment-related com-
plications. In a phase II randomized trial published in
2009,21 40 patients were randomized to HD-MTX and 39
patients to HD-MTX+HD-AraC. Three of 4 treatment-
related deaths occurred in the combination arm (7.7%).
These three studies7,20,21 did not report TRM according to
age. Of note, all 4 treatment-related deaths in our study
occurred in patients aged 64 years or older. Thus, the TRM
in the elderly age subgroup in our study was 11.1% as
compared to 2.6% in the younger patients. Given that
HD-AraC-related toxicity was much more pronounced
than toxicity related to HD-MTX, and in particular given
that all 4 treatment-related deaths in the present study
occurred after HD-AraC, it seems reasonable to suggest
that this agent should be omitted from the treatment reg-
imen, especially for elderly patients. It is an open question,
however, as to whether AraC should be replaced by
another agent or not.
Another feature of interest in PNSCL is the need for
local treatment of the CSF compartment as a prerequisite
for disease control. Here, the Bonn group reported early
relapses and a median duration of response of ten months
in younger patients (median age 53, range 27-59 years),
who did not receive intraventricular treatment, but other-
wise the same systemic therapy as in the original Bonn
regimen, arguing for the need of CSF-targeted therapy.22
While the collective experience from the two Bonn stud-
ies7,22 indicates the need for intraventricular treatment, two
retrospective analyses did not find that intrathecal
chemotherapy had any impact on survival.23,24 Moreover,
Omuro et al.25 reported disappointing results of a retro-
spective study of 64 patients with a median age of 47
years who had a median PFS of 12 months only, despite
the fact that intrathecal treatment consisting of the same
agents  (MTX, AraC and methylprednisolone) was part of
both the induction treatment and a maintenance phase.
These observations pinpoint a crucial feature in the
PNSCL patients, that a way needs to be found to obtain
local tumor control.  In our treatment design, we applied
intraspinal administration of liposomal cytarabine, which
has previously been used in the treatment of lep-
tomeningeal cancer metastasis,26 including lymphomatous
meningitis.27 It should be stressed, however, that the effi-
cacy of liposomal cytarabine in PCNSL has still not been
determined. Our study was not designed to evaluate a sin-
gle agent of the regimen and our results do not allow any
conclusion to be drawn as to the efficacy of liposomal
cytarabine. Given the small number of cases with lym-
phoma detected in the spinal fluid in the present study, we
cannot draw any conclusions as to whether liposomal
cytarabine was effective or even necessary to eradicate
lymphoma cells from the spinal fluid compartment. We
found also a discrepancy between cytological and flow
E.J. Pulczynski et al.
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Figure 2. (A) Response duration after complete remission. 
(B) Response duration after complete remission according to age.
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P=0.33
cytometry analysis of the spinal fluid. It is well document-
ed in the literature that flow cytometry is a more sensitive
method than cytology,28 but flow cytometry in our study
was positive in only 2 cases as compared to 8 cases detect-
ed by cytology. The analysis of spinal fluid was not cen-
tralized and was, therefore, performed at several different
laboratories, which is a drawback of the multicenter
design of our study. 
Furthermore, concerns have been raised regarding neu-
rotoxicity related to liposomal cytarabine, administered
either alone or in combination with systemic chemother-
apy.29 In the present study, a total of 200 liposomal cytara-
bine treatments were delivered to 66 patients, with 15
patients experiencing neurological symptoms grade 2-4,
11 of whom had received liposomal cytarabine within
two weeks before onset of symptoms. However, the neu-
rological complications experienced during therapy in the
present study cannot be ascribed exclusively to liposomal
cytarabine, since other agents, in particular HD-MTX and
ifosfamide used concomitantly, can also give rise to drug-
related neurotoxicity.  Moreover, 4 of the 15 patients men-
tioned above were not exposed to liposomal cytarabine
prior to the development of neurological symptoms. 
Ocular lymphoma, reported to occur in 3%-14% of
PCNSL patients,25,30 was found in 4 of 66 patients in our
study (6%). None of them completed treatment due to
poor clinical condition, toxicity or progressive disease.
Additional treatment in case of ocular lymphoma besides
the study treatment planned for all patients was not part
of our protocol. Optimal treatment for intraocular lym-
phoma remains to be defined. 
Both the route and the timing of MTX administration
should be considered as factors influencing the treatment
results. In most studies, HD-MTX has been administered
at intervals no longer than 21 days. The HD-MTX sched-
ule of the present study (Table 1) entailed no MTX deliv-
ery through six weeks (i.e. from the second to the third
HD-MTX cycle). This was also the case in the Bonn regi-
men when given without intraventricular therapy.22 In
comparison, intraventricular MTX, AraC and methylpred-
nisolone was delivered during all six induction chemother-
apy courses in the original Bonn regimen using the same
systemic HD-MTX schedule, thus avoiding a 6-week peri-
od of no MTX delivery. Theoretically, the inferior results
of the Bonn regimen without intraventricular treatment,
as well as the results in the present study as compared to
the original Bonn regimen, could be due to lymphoma
growth or leptomeningeal seeding during the time when
the tumor was not exposed to MTX. Consequently, in
future studies, attention should be paid to the drug inten-
sity of MTX delivery whatever the route of administra-
tion.
In conclusion, the main feature of the present study is its
focus on elderly patients, who have so far not received
much attention. Our approaches of de-escalating induc-
tion and introduction of maintenance therapy have pro-
vided results which are among the most favorable ever
reported in elderly PCNSL patients.5,30,31,32 Thus, moving
the focus to the maintenance phase seems to indicate that
temozolomide maintenance has been of benefit regarding
sustained remission, since relapse after achieving CR
occurred in only 5 of 18 elderly patients (28%) as com-
pared to 17 of 27 patients (63%) in the younger subgroup
who did not receive maintenance treatment. On the other
hand, the induction regimen applied in the elderly sub-
group was still too toxic, given that 3 of 4 treatment-relat-
ed deaths occurred in this age group. We propose a main-
tenance treatment in all responding patients not fit for
more aggressive therapies in order to improve disease con-
trol and further de-escalation of induction in elderly
patients to reduce toxicity.  
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